New US lawsuit over insulin prices will have minimal impact on Novo Nordisk, says analyst

A California lawsuit could potentially move the needle slightly in early Friday trading, says an analyst, but will likely be added to the pile of other legal cases of non-material impact. 
Photo: Novo Nordisk / Pr
Photo: Novo Nordisk / Pr
by marketwire, translated by daniel pedersen

Another lawsuit has hit Novo Nordisk and its rivals in the US, Eli Lilly and Sanofi, as the state of California has leveled accusations against the insulin industry for overpricing products.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading